AstraZeneca will fall to Pfizer once the price is right, even if British politicians are jumping up and down

Only the shareholders have the ability to refuse and they’re mandated to seek the best return

When Kraft bid for Cadbury, I recall having a conversation with someone senior at the British chocolate maker as to what would be an acceptable offer.

“I reckon you’ve got 850p in your head,” I said. The Cadbury man spluttered, and tried to say there were other considerations as well. He stressed that he and his colleagues were determined to stand and fight, to do everything they could to halt the would-be US acquirer. He was not going to be drawn on a discussion about the numbers. Note, though, that he did not deny it either.

This was not rocket science on my part. All I’d done was do a ring round of a few City analysts and ask them for the figure at which they thought Cadbury shareholders would run up the white flag – or rather, the investor institutions would walk off with a fat profit, leaving the historic British firm in the hands of the US predator.

Forget the huffing and puffing, the raging about a foreigner coming in. That sort of stuff is for the politicians, unions, local communities where jobs may be threatened. They are right to be concerned – such bids are not necessarily a good thing for the UK. But from Day One, the City will have had a target number in mind. Pay that and Cadbury is yours; fall short and you won’t get it.

So it is with Pfizer and AstraZeneca. What’s the price which the AstraZeneca board is holding out for, and if it’s achieved, will see it throw in the towel, heads held high? I reckon £59-£60 a share. Already, Pfizer has tabled a bid of £50. Up it a bit more, and again, until you reach £59, and the British firm will fall. To be fair, some shareholders have indicated that they would prefer to stick with AstraZeneca, but this is what most of the City institutions are likely to be looking for.

Let’s be clear: they’re one of two sets of people who matter in this proposed takeover. The other is the Eurocrats in Brussels. This is a big enough deal to come within EU mergers regulations. Only the European Commission can block it, and it’s not clear whether it would have reason to, since the criterion by which it assesses such mergers is solely the effect on competition, not on such things as jobs or the science base.

I’ve left out another grouping; one that we British might suppose carries weight and has enormous power in these affairs. That, of course, is our own political masters at Westminster.

The truth is there is absolutely nothing they can do to prevent Pfizer coming in and grabbing AstraZeneca. At the moment there is a lot of posturing going on, with Ed Miliband, in particular, jumping up and down, accusing David Cameron of acting as “cheerleader” for the American company’s £63bn move.

But Ed, be honest now. If you were Prime Minister today, what could you do to shoo Pfizer away? The answer, as you and I well know, is precisely nothing. It’s possible that a clause could be added to the Enterprise and Regulatory Reform Act 2013, adding research and development to the types of mergers that can prompt government intervention, namely those affecting our defence interests, media, and financial stability. However, even if that were to be done, ministers would still be powerless to act since the case falls under EU jurisdiction, and would not come to them for a decision.

In theory, the UK could press to reform the EU regulations, so that mergers of this kind would be judged under different criteria. But that would take an age, and would definitely fall outside the timeframe of the mooted Pfizer-AstraZeneca marriage. If Ed Miliband is saying that, as PM, the UK would seek such a change, then good luck to him in achieving EU-wide consensus on that one.

Vince Cable knows this, too. The Business Secretary appears to be opposed to the deal, but is markedly unspecific on the point of how he, as the Cabinet member in charge of such things, could actually do anything about it. Mr Cable wants to be seen to be more caring than the Tories – and to be fair, he probably is more concerned about the impact on jobs and our R&D expertise – and he’s anxious that Labour does not present itself as the only party that backs British business. But while he says he is concerned about the bid on “public interest grounds”, there is precious little he can do to put his words into action.

Ironically, in his four years as Business Secretary, if he cared so much about this, Mr Cable could have sought to change the rules to make it more difficult for foreigners to buy up our assets. His department passed new legislation on the competition rules just last year, while the European Commission has been consulting the UK (and other countries) on reforming its merger regulations. But what has he done about it? Zero. Mr Cable even made a point of saying Lord Heseltine was wrong in his review into UK economic growth to say there should be a failsafe mechanism for UK government intervention in takeovers of key UK assets by overseas companies. It’s a bit rich of Mr Cable, now, to turn round and complain about Pfizer.

Mr Cameron is aware of all this as well. Asking the Cabinet Secretary Sir Jeremy Heywood and Treasury mandarin Sir John Kingman to assess the Pfizer plan is pure window-dressing, nothing more, nothing less. It’s the classic ruse of a PM wanting to be seen to be doing something, a ploy designed to secure some decent PR, when he knows that in reality Sir Jeremy and Sir John’s findings have no real significance whatsoever.

All the intrepid duo can do is dream up some assurances that Pfizer must sign up to in order to obtain government backing. These though, will have no legal authority.

Pfizer has thought of some commitments of its own, saying in a letter to Mr Cameron that the number of jobs in the UK will be held constant for five years, a new R&D park will still be built in Cambridge, and 20 per cent of Pfizer’s group science will be domiciled in Britain.

But the jobs guarantee is only provided unless “circumstances significantly change”; the Cambridge site was already going to be developed; and 20 per cent of the combined group’s staff would be in the UK anyway. In other words, the letter is full of platitudes and get-outs. Pfizer can tear it up four years hence and the government of the day, even one with Mr Miliband at the helm, will only be able to watch, powerless.

Pfizer’s bosses are only human. The best hope of stopping them is to scream and shout – they have no desire to be unpopular, they will crave acceptance. There are real issues at stake here and if the anti-Pfizer movement is vocal enough it may well resonate in the US giant’s boardroom.

Likewise, at least two Parliamentary select committees are gearing up to interview the Pfizer and AstraZeneca management. Again, that is not something the Pfizer folk will relish. We should, though, be under no illusion: it is only noise. The MPs can recommend as much as they like but select committees have no decision-making powers even here in the UK, still less in Brussels, so they’re in no position to head off the Pfizer purchase.

We’ve been here before, with Kraft. Its chief, Irene Rosenfeld, did not even deign to appear before MPs, such was their supposed hold over her. Public promises as to future conduct were made by her company and then it ignored them. Why? Because it can.

If Pfizer is made of similarly stern stuff, it too can behave the same way. In the end, despite a massive amount of energy, and money, expended on anti-Kraft campaigns, MPs and others taking to the ramparts, sections of the media going wild with fury, the British company fell. What was the price it went for? 850p a share. It was always going to.

AstraZeneca, sadly, is no different. Only the shareholders have the ability to refuse and they’re mandated to seek the best return on their investments for their clients, the funds in which we hold our pensions. Their decisions may or may not be good for the UK, but unless the politicians want to add policy on large mergers to the list of items to  be renegotiated with Brussels, then it is  what it is.

News
Russia Today’s new UK channel began broadcasting yesterday. Discussions so far have included why Britons see Russia as ‘the bad guy’
news

New UK station Russia Today gives a very bizarre view of Britain

News
people
News
people
Voices
Left: An illustration of the original Jim Crowe, played by TD Rice Right: A Couple dressed as Ray and Janay Rice
voices

By performing as African Americans or Indians, white people get to play act a kind of 'imaginary liberation', writes Michael Mark Cohen

PROMOTED VIDEO
News
i100
Arts and Entertainment
Hand out press photograph/film still from the movie Mad Max Fury Road (Downloaded from the Warner Bro's media site/Jasin Boland/© 2014 Warner Bros. Entertainment Inc.)
films'You have to try everything and it’s all a process of elimination, but ultimately you find your path'
Arts and Entertainment
Imelda Staunton as Dolores Umbridge in the Harry Potter films
books

New essay by JK Rowling went live on Pottermore site this morning

News
people

Top Gear presenter is no stranger to foot-in-mouth controversy

Arts and Entertainment
Keira Knightley and Benedict Cumberbatch at the premiere of The Imitation Game at the BFI London Film Festival
filmsKeira Knightley tried to miss The Imitation Game premiere to watch Bake Off
News
i100
News
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

The benefits of Recruitment at SThree...

£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...

Trainee Recruitment Consultants

£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...

Finance Assistant - Part time - 9 month FTC

£20000 - £23250 Per Annum pro rata: Clearwater People Solutions Ltd: Pro rata ...

Marketing Manager

£40 - 48k + Benefits: Guru Careers: We are seeking a Marketing Manager to join...

Day In a Page

The drugs revolution starts now as MPs agree its high time for change

The drugs revolution starts now as MPs agree its high time for change

Commons debate highlights growing cross-party consensus on softening UK drugs legislation, unchanged for 43 years
The camera is turned on tabloid editors in Richard Peppiatt's 'One Rogue Reporter'

Gotcha! The camera is turned on tabloid editors

Hugh Grant says Richard Peppiatt's 'One Rogue Reporter' documentary will highlight issues raised by Leveson
Fall of the Berlin Wall: It was thanks to Mikhail Gorbachev that this symbol of division fell

Fall of the Berlin Wall

It was thanks to Gorbachev that this symbol of division fell
Halloween 2014: What makes Ouija boards, demon dolls, and evil clowns so frightening?

What makes ouija boards and demon dolls scary?

Ouija boards, demon dolls, evil children and clowns are all classic tropes of horror, and this year’s Halloween releases feature them all. What makes them so frightening, decade after decade?
A safari in modern Britain: Rose Rouse reveals how her four-year tour of Harlesden taught her as much about the UK as it did about NW10

Rose Rouse's safari in modern Britain

Rouse decided to walk and talk with as many different people as possible in her neighbourhood of Harlesden and her experiences have been published in a new book
Welcome to my world of no smell and odd tastes: How a bike accident left one woman living with unwanted food mash-ups

'My world of no smell and odd tastes'

A head injury from a bicycle accident had the surprising effect of robbing Nell Frizzell of two of her senses

Matt Parker is proud of his square roots

The "stand-up mathematician" is using comedy nights to preach maths to big audiences
Paul Scholes column: Beating Manchester City is vital part of life at Manchester United. This is first major test for Luke Shaw, Angel Di Maria and Radamel Falcao – it’s not a game to lose

Paul Scholes column

Beating City is vital part of life at United. This is first major test for Shaw, Di Maria and Falcao – it’s not a game to lose
Frank Warren: Call me an old git, but I just can't see that there's a place for women’s boxing

Frank Warren column

Call me an old git, but I just can't see that there's a place for women’s boxing
Adrian Heath interview: Former Everton striker prepares his Orlando City side for the MLS - and having Kaka in the dressing room

Adrian Heath's American dream...

Former Everton striker prepares his Orlando City side for the MLS - and having Kaka in the dressing room
Simon Hart: Manchester City will rise again but they need to change their attitude

Manchester City will rise again but they need to change their attitude

Manuel Pellegrini’s side are too good to fail and derby allows them to start again, says Simon Hart
Isis in Syria: A general reveals the lack of communication with the US - and his country's awkward relationship with their allies-by-default

A Syrian general speaks

A senior officer of Bashar al-Assad’s regime talks to Robert Fisk about his army’s brutal struggle with Isis, in a dirty war whose challenges include widespread atrocities
‘A bit of a shock...’ Cambridge economist with Glasgow roots becomes Zambia’s acting President

‘A bit of a shock...’ Economist with Glasgow roots becomes Zambia’s acting President

Guy Scott's predecessor, Michael Sata, died in a London hospital this week after a lengthy illness
Fall of the Berlin Wall: History catches up with Erich Honecker - the East German leader who praised the Iron Curtain and claimed it prevented a Third World War

Fall of the Berlin Wall

History catches up with Erich Honecker - the East German leader who praised the Iron Curtain and claimed it prevented a Third World War
How to turn your mobile phone into easy money

Turn your mobile phone into easy money

There are 90 million unused mobiles in the UK, which would be worth £7bn if we cashed them in, says David Crookes